Lupus clinical trials at UCSF
6 research studies open to eligible people
Lupus happens when the immune system attacks healthy body tissue. UCSF studies include a trial of anifrolumab for skin lupus issues. Researchers test rapcabtagene autoleucel for severe lupus kidney complications. Another investigation checks obinutuzumab's use in adolescent lupus nephritis.
2-stage, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
open to eligible people ages 18-70
This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with cutaneous lupus erythematosus (CLE).
San Francisco, California and other locations
Rapcabtagene Autoleucel in Systemic Lupus Erythematosus (SLE) Patients With Active, Refractory Lupus Nephritis (LN)
open to eligible people ages 18-65
The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) versus Standard of Care (SOC) in patients with systemic lupus erythematosus (SLE) with active, refractory lupus …
San Francisco, California and other locations
Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
open to eligible people ages 5-17
This phase II, randomized, double-blind, placebo-controlled study is designed to evaluate the safety, efficacy and pharmacokinetics (PK) of obinutuzumab in adolescent participants (AP) aged 12 to less than 18 with biopsy-confirmed proliferative…
San Francisco, California and other locations
Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old
open to eligible people ages 18-75
In this study, researchers will learn more about the use of felzartamab in people with active lupus nephritis, also known as LN. In people with LN, antibodies build up in the glomeruli of the kidneys. Antibodies are proteins in the blood used by the …
San Francisco, California and other locations
Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
open to eligible people ages 8-20
The study is a 1-year 2-part double-blinded placebo controlled 2-arm clinical trial. Treatment arms are (1) MMF dosed as per body-surface area (MMFBSA; 600mg/m2 body surface area per dose about every 12 hours) and (2) pharmacokinetically-guided…
San Francisco, California and other locations
VIBRANT: VIB4920 for Active Lupus Nephritis
open to eligible people ages 18 years and up
This is a multi-center double-blind placebo controlled clinical trial evaluating the efficacy of VIB4920 combined with mycophenolate mofetil (MMF) and prednisone in achieving a renal response in participants with active lupus nephritis (LN).
San Francisco, California and other locations
Our lead scientists for Lupus research studies include David Wofsy, M.D. Raymond Hsu Emily Von Scheven.
Last updated: